Adriamycin cardiotoxicity: a survey of 1273 patients

摘要: Valuable information was collected on the medical history and clinical course of 1273 patients entered in trials with Adriamycin (ADR) carried out 12 European cancer centers. A coded patient form used for data collection each center by a qualified physician following guideline which discussed accepted all participants. The aim study to define incidence, characteristics, possible co-factors cardiomyopathy (CMP) treated combination chemotherapy regimens including ADR. mean total dose ADR 268 mg/m2 (range, 15--1251 mg/m2), 5.1% received greater than 550 mg/m2. "definite" ADR-related CMP observed 1.7% cases; another 3% cases were reported as "possible" ADR-CMP since role played drug could not be clearly defined. "Definite" fatal eight (0.6%) while 13 (1.0%). Among examined, ones found significantly associated occurrence ADR-CMP: (a) ADR; (b) vincristine when given both before concomitantly (c) bleomycin (d) radiotherapy mediastinum Furthermore, none 182 receiving slow infusion developed ADR-CMP, 2% bolus injection did so. two pre-existing pathologic conditions (electrocardiogram [ECG] abnormalities hypertension) but treatment-related mentioned above. Other variables such sex, age, type, baseline liver function, cyclophosphamide treatment, seem influence risk ADR-CMP. Data ECG changes occurring during treatment also their incidence strictly related frequency monitoring.